CClinicalTrials.gg
Sign In
Status unknownNCT04022421Updated Jul 25, 2019

Hydroxychloroquine Efficacy on Behcet's Disease Thrombosis

An interventional study of Hydroxychloroquine in Behcet's Syndrome, Vascular Type, sponsored by Assiut University. Status unknown at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-25.

Sponsored by Assiut University · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jul 2019), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Oct 2018, registered Jul 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Patients diagnosed with Behcet's disease will be randomized to administeration of hydroxychloroquine. Assessment will be done for the patients at baseline and every one month in the first three months and then quarterly for one year.

02

Conditions studied

  • Behcet's Syndrome, Vascular Type

Browse trials for

03

In context

Behcet Syndrome

136 studies on the registry are indexed under Behcet Syndrome; 43 are open to participants now.

This study's planned enrollment of 50 is close to the median of 50 across 70 interventional studies indexed under Behcet Syndrome.

Browse Behcet Syndrome studies →

Lead sponsor

Assiut University is the lead sponsor of 4,916 studies on the registry; 2,113 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • All patients diagnosed with Behcet's disease on any DMARDs

Exclusion criteria

Exclusion Criteria:

  • Patients with critical conditions
  • Patients with hypersensitivity or adverse drug reactions to hydroxychloroquine.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    hydroxychloroquine arm

    Drug: Hydroxychloroquine

Interventions

  • DrugHydroxychloroquine

    the drug will be taken by one group of the patients daily at a dose of 400mg

06

What researchers measure

Primary outcomes

  1. Prevention of the recurrence of thrombotic events

    number of relapses is expected to fall with the longterm use of the drug

    Time frame: 6 months- one year

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04022421
Lead sponsor
Assiut University
Responsible party
Alaa Abdelkhalik Ahmed Mohamed (Principal Investigator, Assiut University) — Principal investigator
First posted
Jul 17, 2019
Start date
Oct 1, 2018
Primary completion
Aug 2019 (estimated)
Completion
Oct 2019 (estimated)
Last update
Jul 25, 2019

Study contacts

Alaa Mohamed, Post-doctor
Contact
a.a.a.mohamed@aun.edu.eg
+20882413177

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Behcet Syndrome→

Other studies from this sponsor

Assiut University

Start the discussion